Marcelo Bigal, Ventus Therapeutics CEO

Up­dat­ed: RA Cap­i­tal and Soft­Bank head up the lat­est nine-fig­ure crossover, this time for Ven­tus. Will an IPO soon fol­low?

A biotech pre­vi­ous­ly backed by Ver­sant and GV is un­veil­ing its newest fi­nanc­ing round, com­ing with a slate of blue-chip in­vestors that could sig­nal an IPO in the near fu­ture.

Ven­tus Ther­a­peu­tics closed a $140 mil­lion Se­ries C on Wednes­day morn­ing, a round led by the sec­ond Soft­Bank Vi­sion Fund and RA Cap­i­tal. The biotech said in a press re­lease the mon­ey will large­ly be used to scale its sec­ond plat­form and help push its lead drug pro­gram clos­er to the clin­ic.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.